Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys:Pathomechanistic Role of Peripheral Sympathetic System and Neuropeptide Y

Toxicologic Pathology

Volumn 42, Issue 4, 2014, Pages 684-695

  Hoffmann, Peter ^a   Bentley, Phil ^a   Sahota, Pritam ^a   Schoenfeld, Heidi ^a   Martin, Lori ^a   Longo, Linda ^a   Spaet, Robert ^a   Moulin, Pierre ^a   Pantano, Serafino ^a   Dubost, Valerie ^a   Lapadula, Dan ^a   Burkey, Bryan ^b   Kaushik, Virendar ^b   Zhou, Wei ^a   Hayes, Michael ^a   Flavahan, Nick ^c   Chibout, Salah Dine ^b   Busch, Steve ^a   Morton, Daniel ^c   Tomlinson, Lindsay ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

dipeptidyl peptidase 4; monkey; neuropeptide Y; skin lesions; vascular; vildagliptin

Indexed keywords

ADAMANTANE; DIPEPTIDASE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NEUROPEPTIDE Y; NITRILE; NORADRENALIN; PYRROLIDINE DERIVATIVE; VILDAGLIPTIN;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD PRESSURE; BLOOD VESSEL INJURY; CHEMICALLY INDUCED; COLD; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MACACA FASCICULARIS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGICAL STRESS; SKIN; SKIN DISEASE; URINE; VASOCONSTRICTION; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; COLD STRESS; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; ENVIRONMENTAL TEMPERATURE; EX VIVO STUDY; FEMALE; HEART RATE VARIABILITY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN HYPERTROPHY; SKIN NECROSIS;

ADAMANTANE; ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; COLD TEMPERATURE; DIPEPTIDASES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MACACA FASCICULARIS; NEUROPEPTIDE Y; NITRILES; NOREPINEPHRINE; PYRROLIDINES; SKIN; SKIN DISEASES; STRESS, PHYSIOLOGICAL; VASCULAR SYSTEM INJURIES; VASOCONSTRICTION;

EID: 84902081458     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313516828     Document Type: Article

References (30)

1. Boschmann M. Engeli S. Dobberstein K. Budziarek P. Strauss A. Boehnke J. Sweep F. Luft F. C. He Y. Foley J. E. Jordan J. (2008). Dipeptidyl-peptidase IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 92, 1249–55.
2. Burkey B. Hoffmann P. Hassiepen U. Trappe J. Judes M. Foley J. E. (2008). Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 10, 1057–61.
3. Chen W. T. Kelly T. Ghersi G. (2003). DPPIV, seprase and related serine peptidases in multiple cellular functions. Curr Top Dev Biol 54, 207–32.
4. Chotani M. A. Flavahan S. Mitra S. Daunt D. Flavahan N. A. (2000). Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Cir Physiol 278, H1075–83.
5. Cohen R. A. Vanhoutte P. M. (1995). Endothelium-dependent hyperpolarization: Beyond nitric oxide and cyclic GMP. Circulation 92, 3337–49.
6. Copeland R. A. (2000). Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. New York: Wiley-Interscience.
7. Coppock R. W. Mostrom M. S. Simon J. McKenna D. J. Jacobsen B. Szlachta H. L. (1989). Cutaneous ergotism in a herd of dairy calves. JAVMA 194, 549–51.
8. Creutzfeldt W. (2001). The entero-insular axis in type 2 diabetes: Incretins as therapeutic agents. Ex Clin Endocrinol Diabetes 109, S288–303.
9. Elizondo R. S. (1988). Primate models to study eccrine sweating. Am J Primatol 14, 265–76.
10. Flavahan N. A. (2005). Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating alpha2-adrenoceptors. J Pharmacol Ex Ther 313, 432–39.
11. Grouzmann E. Livio F. Buclin T. (2009). Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: An increased risk of angioedema. Hypertension 54, 468–70.
12. Hill J. W. Urban H. Xu M. Levine J. E. (2004). Estrogen induces neuropeptide Y (NPY) Y1 receptor gene expression and responsiveness to NPY in gonadotrope-enriched pituitary cell cultures endocrinology. Endocrinology 145, 2283–90.
13. S.L., Jin, V.V.M., Han, J.G., Simmons, A.C., Towle, J.M., Lauder, P.K., Lund, Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain: An immunocytochemical study, J Comp Neurol, (1988), 271, 519-532
14. Johnson G. S. Elizondo R. S. (1974). Eccrine sweat gland in Macaca mulatta: Physiology, histochemistry, and distribution. J Appl Phyisol 37, 814–20.
15. Kalra P. S. Dube M. G. Xu B. Farmerie W. G. Kalra S. P. (1998). Neuropeptide Y (NPY) Y1 receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: Evidence for a hypothalamic site for concurrent development of leptin resistance. J Neuroendocrinology 10, 43–49.
16. Lankas G. R. Leiting B. Roy R. S. Eiermann G. J. Beconi M. G. Biftu T. Chan C. C. Edmondson S. Feeney W. P. He H. Ippolito D. E. Kim D. Lyons K. A. Ok H. O. Patel R. A. Petrov A. N. Pryor K. A. Qian X. Reigle L. Woods A. Wu J. K. Zaller D. Zhang X. Zhu L. Weber A. E. Thornberry A. (2005). Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54, 2988–94.
17. Larsen P. J. Tang-Christensen M. Holst T. T. Orskov C. (1997). Distribution of glucagon-like peptide 1 and other preproglucagon-peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257–70.
18. M., Ligueros-Saylan, J.E., Foley, A., Schweizer, A., Couturier, W., Kothny, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials, Diabetes Obes and Metab, (2010), 12, 495-509
19. Marney A. Kunchakarra S. Byrne L. Brown N. J. (2010). Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56, 728–33.
20. McIntosh C. H. Demuth H. U. Pospisilik J. A. Pederson R. (2005). Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regul Pept 128, 159–65.
21. Pantano S. Dubost V. Darribat K. Couttet P. Grenet O. Busch S. Moulin P. (in press). Differential expression of dipeptidyl peptidase IV in human versus cynomolgus monkey skin eccrine sweat glands. J Mol Histol. 2013 Dec; 44(6):733–47. doi: 10.1007/s10735-013-9524-5. Epub 2013 Jul 24.
22. Sato K. Sato F. (1987). Effect of VIP on sweat secretion accumulation in isolated simian eccrine glands. Am J Physiol 253, R935–41.
23. Sedo A. Malik R. (2001). Dipeptidyl peptidase IV-like molecules: Homologues proteins or homologues activities? Biochim Biophys Acta 1550, 107–16.
24. Segel I. H. (1975). Enzyme Kinetics: Behavior and Analysis of Rapid-equilibrium and Steady-state Enzyme Systems. Hoboken, NJ: Wiley-Interscience.
25. Spinazzi R. Andreis P. G. Nussdorfer G. G. (2005). Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions. Int J Mol Med 15, 3–13.
26. Steinhoff M. Stander S. Seeliger S. Ansel J. C. Schmelz M. Luger T. (2003). Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 139, 1479–88.
27. Villhauer E. B. Brinkman J. A. Naderi G. B. Burkey B. F. Dunning B. E. Prasad K. Mangold B. L. Russell M. E. (2003). 1-(3-hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46, 2774–89.
28. Walker P. Grouzmann E. Burnier M. Waeber B. (1991). The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 12, 111–15.
29. Yamamoto H. Lee C. E. Marcus J. N. Williams T. D. Overton J. M. Lopez M. E. Hollenberg A. N. Baggio L. Saper C. B. Drucker D. J. Elmquist J. K. (2002). Glucagon-like peptide receptor stimulation increased blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110, 43–52.
30. Zukowska-Grojec Z. Karwatowska-Prokopczuk E. Fisher T. A. Ji H. (1998). Mechanisms of vascular growth-promoting effects of neuropeptide Y: Role of its inducible receptors. Regul Pept 75–76, 231–38.